home / stock / scyx / scyx news

SCYX News and Press, SCYNEXIS Inc. From 04/24/23

Stock Information
Company Name: SCYNEXIS Inc.
Stock Symbol: SCYX
Market: NASDAQ
Website: scynexis.com
Menu
SCYX SCYX Quote SCYX Short SCYX News SCYX Articles SCYX Message Board
Get SCYX Alerts

News, Short Squeeze, Breakout and More Instantly...
SCYX - Cidara earns $20M milestone payment on FDA nod for antifungal

2023-04-24 09:13:55 ET Cidara Therapeutics ( NASDAQ: CDTX ) announced Monday that it received a $20M milestone payment from its partner Melinta Therapeutics ( OTCPK:MLNTQ ) following the FDA approval of candidemia treatment Rezzayo last month. The U.S. approved the once we...
SCYX - SCYNEXIS to Present Ibrexafungerp Data at the 33rd Annual European Congress of Clinical Microbiology & Infectious Diseases (ECCMID) April 15-18 in Denmark

JERSEY CITY, N.J., April 13, 2023 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, today announced the presentation of interim data across a diverse array of infecti...

SCYX - WAL, SCYX and NMTR among pre-market losers

2023-04-05 08:31:04 ET Secoo Holding ( SECO ) -22% . The NFT Gaming Company ( NFTG ) -16% . Assure Holdings ( IONM ) -12% . Bullfrog AI Holdings ( BFRG ) -11% . Alarum Technologies ( ALAR ) -10% . Guardforce AI ( GFAI ) -8%...

SCYX - Scynexis: Licensing Deal With GSK, Upgrading To A Hold Rating From A Sell

2023-03-31 11:47:43 ET Summary GSK and SCYNEXIS signed an exclusive licensing agreement for Brexafemme, an FDA-approved medicine for vulvovaginal candidiasis. GSK will pay SCYNEXIS $90 million upfront, with additional milestone payments and royalties. SCYNEXIS retains rights to ot...
SCYX - SCYNEXIS GAAP EPS of -$0.30 beats by $0.10, revenue of $1.4M beats by $0.13M

2023-03-31 08:39:40 ET SCYNEXIS press release ( NASDAQ: SCYX ): Q4 GAAP EPS of -$0.30 beats by $0.10 . Revenue of $1.4M (+133.3% Y/Y) beats by $0.13M . SCYNEXIS ended Q4 2022 with cash, cash equivalents and short-term investments of $73.5 million, and upon clos...

SCYX - SCYNEXIS Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update

SCYNEXIS announced it has signed an exclusive agreement with GSK to commercialize and further develop BREXAFEMME ® (ibrexafungerp tablets) for all indications. GSK will make an upfront payment to SCYNEXIS of $90 million, as well as potential future milestones and tiered royalties. ...

SCYX - Penny Stocks: Technical Approach to Finding Opportunities 

2023-03-31 06:00:00 ET 3 Ways to Use Technical Analysis to Find Winning Penny Stocks Penny stocks, often defined as shares trading below $5, have long been a magnet for investors seeking opportunities to capitalize on the potential for rapid growth and high returns. While many perceive ...
SCYX - PRQR, FC and WINT among mid-day movers

2023-03-30 12:33:44 ET Gainers: SCYNEXIS ( SCYX ) +54% . Palisade Bio ( PALI ) +36% . Windtree Therapeutics ( WINT ) +39% . Toro ( TORO ) +34% . F45 Training ( FXLV ) +32% . Pyxis Oncology ( PYXS ) +29% . EVgo ( ...

SCYX - SCYNEXIS, Palisade top healthcare gainers; AngioDynamics, Avidity lead losers' pack

2023-03-30 10:02:34 ET Gainers: SCYNEXIS ( SCYX ) +61% . Palisade Bio ( PALI ) +33% . Biophytis ( BPTS ) +10% . RenovoRx ( RNXT ) +9% . VYNE Therapeutics ( VYNE ) +9% . Losers: AngioDynamics ( ANGO ) -28% . ...

SCYX - SCYNEXIS jumps 92% on licensing deal with GSK for anti-fungal agent

2023-03-30 07:40:40 ET GSK ( NYSE: GSK ) and New Jersey-based biotech SCYNEXIS ( NASDAQ: SCYX ) announced an exclusive license agreement on Thursday for Brexafemme (ibrexafungerp tablets), an FDA-approved treatment for certain fungal infections. In the pre-market, ...
Previous 10 Next 10